AstraZeneca's Motavizumab May Be The Canary In The Follow-On Coal Mine
Executive Summary
When a significant drug application hits a snag, it can sometimes feel like the whole industry stumbles. Such is the case with AstraZeneca PLC’s motavizumab, which protects against the effects of respiratory syncytial virus and recently failed to get a timely regulatory approval. This suggests the government agency’s standards may be changing on a range of issues, from comparative effectiveness to data integrity.
You may also be interested in...
Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune
If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)
Comparative Effectiveness Reaches Into Drug Reviews, FDA Documents Show
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.